| INTRODUCTION
Sulphonylureas (SUs) were discovered in 1942 when French researchers observed severe hypoglycaemia in patients receiving sulphonamide treatment for typhoid fever. 1 It was recognized that sulphonamide-induced hypoglycaemia mimicked the action of insulin. 2, 3 SUs were introduced to clinical practice in the 1950s. The last 10 years have seen major advances in type 2 diabetes mellitus (T2DM) pharmacotherapy. [4] [5] [6] Such are these advances, debate has been provoked that SUs are no longer a justified second line therapy because of their inconsistent cardiovascular (CV) and mortality data 7 , 8 risks of hypoglycaemia, body weight gain and secondary failure. 9, 10 By 2013, SU prescribing as add-on to metformin had fallen to 41.4%
(95% CI, 41.1-41.7%) 11 with new favour shown towards dipeptidyl peptidase-4 (DPP-4) inhibitors. Notably, this was before the prescribing prevalence of glucagon-like peptide-1 receptor agonists (GLP1-RAs) and sodium-glucose co-transporter-2 (SGLT-2) inhibitors started to increase 12, 13 The controversies regarding whether SUs should continue to be used as second line therapy in T2DM treatment have been heavily debated, 14 including at The American Diabetes Association annual scientific sessions in 2015. 15, 16 It is hoped that the results of the CARO- (Table 1) .
SUs were identified as causing beta-cell depolarization in the 1960s 18 ; it was later noted that this was because of a decrease in the potassium permeability of the beta-cell membrane. 19 Patch clamp electrophysiology studies found that SUs interact with and close ATPsensitive potassium (K ATP ) channels. 20 K ATP channel closure decreases the permeability of the beta-cell membrane to potassium ions, which depolarizes the membrane. 21 SUs, unlike glucose, inhibit the K ATP channel directly, causing depolarization through Ca 2 influx, resulting in glucose-independent insulin secretion. 22 Importantly, this differentiates SUs from newer therapies (GLP1-RAs and DPP-4 inhibitors) that work in a glucosedependent manner. Along with this first phase of insulin secretion, SUs also induce the later second phase of insulin secretion to induce continuous formation of insulin granules. 23 The [34] [35] [36] These mutations reduce the ability of ATP to close the K ATP channel, 31 thus preventing glucose-induced depolarization and insulin release.
NDM management advanced following a pharmacogenetic study of patients with Kir6.2 mutations. Of the 49 participants, 44 successfully switched from insulin to a high dose SU. 37 The switch was achieved with no episodes of severe hypoglycaemia, no increase in mild-to-moderate hypoglycaemia, and was regardless of the SU used. 33 Physiological studies undertaken before and after the introduction of SUs in patients with activating K ATP channel mutations were striking ( Figure 1 ). Patients had no insulin secretory response to intravenous (IV) glucose or glucagon before transition off insulin. However, following established SU use, there was a large insulin secretory response to glucagon. Similarly, in SU patients, insulin secretion following an oral glucose or mixed meal stimulus was much greater than seen with IV glucose.
These results show that in patients with Kir6.2 mutations, the glycaemic benefit of SUs resulting in near normoglycaemia and insulin cessation, is not because of a direct stimulatory effect of SUs on 42 Therefore, for at least some patients with diabetes, K ATP channel dysfunction contributes to their diabetes aetiology, and these patients may have a hyperpolarized beta-cell. The parallels here with NDM are apparent, suggesting that an appropriate dose of SU may promote GSIS with minimal hypoglycaemia.
| IS THERE A ROLE FOR LOW-DOSE SULPHONYLUREAS?
Henquin described a "sigmoidal hierarchy" between two pathways of GSIS. 43 Firstly, in the direct/triggering pathway whereby SU bind to SUR of the K ATP channel and bring about channel closure, this stimulates insulin secretion and in vitro stimulates insulin secretion in a glucose-independent mechanism. Secondly, in the amplifying/potentiating pathway, in which incretin hormones (GLP-1/GIP), glucagon or arginine act to augment insulin secretion via a rise in cyclic AMP. 38 In patients with T2DM, as is clearly seen in any study of conventional therapeutic dose of SU, this insulin secretion is not entirely glucose-regulated and there is a risk of hypoglycaemia. One can hypothesize that a low-dose SU should potentiate beta-cell insulin secretion in a glucose-dependent mechanism. If true, their effect would raise the beta-cell membrane potential and, through sigmoidal hierarchy, allow activation of the amplifying pathway by glucagon and incretin hormones.
A study of an isolated rat pancreas showed that gliclazide at concentrations one-tenth of those deemed therapeutic (0.25 mcg/ml) potentiated GSIS, without increasing fasting insulin. 44 Similarly, a study on just 20 mcg/kg body weight of glibenclamide in normoglycaemic patients had no effect on fasting insulin secretion. 45 Thus, if a suitably low dose is given, then partial K ATP channel closure will result, the amplifying pathway will be augmented, and GSIS will occur. Interestingly, in a study of single dose vildagliptin and 5 mg glibenclamide, the insulin secretion was increased following oral glucose but there was no greater risk of hypoglycaemia, consistent with glucose regulation of the combined treatment in this study where the oral glucose tolerance test (OGTT) was performed just 30 minute after the glibenclamide dose (i.e. concentrations would have been subtherapeutic). 46 Studies suggest that there is minimal glycaemic benefit of successive dose-escalation of SU. A prospective, case-controlled dose- ug/mL sustained from 3 hour). 54 
| WHAT IS THE MECHANISM OF SULPHONYLUREA FAILURE? ARE SOME SULPHONYLUREAS BETTER THAN OTHERS?
Concern was raised as to the numbers of patients progressing to additional therapy following long-term SU treatment. 55 Although the UK Prospective Diabetes Study (UKPDS) group did not show more rapid failure with SU compared to metformin, the ADOPT study does suggest that SU fail quicker than metformin and rosiglitazone. 10 KaplanMeier analysis showed a cumulative incidence of monotherapy failure at 5 years of 15% with rosiglitazone, 21% with metformin, and 34%
with glyburide. Notably, the ADOPT study assessed newly diagnosed diabetics, with more residual beta-cell function than established T2DM. Progression-to-failure may be provoked by SU-associated body weight gain and fear of hypoglycaemia, leading to non-compliance, however several hypotheses exist for the molecular mechanism of failure.
Firstly, persistent SU closure of the K ATP channels may result in beta-cell apoptosis; this was investigated in cultured human islets. 
however, a 1.49 increase in apoptosis was seen with higher concentration (1000 μmol).
Another hypothesis is that persistent closure of the K ATP channels results in insulin secretory failure without beta-cell death.
Slow-release glibenclamide pellets were implanted into wild-type mice to induce chronic K ATP channel closure. The mice became progressively and persistently diabetic, with reduced insulin secretion in response to hyperglycaemia (p < 0.05). Within 1 week of treatment, wild-type mice had developed almost the same degree of glucose intolerance as K ATP knockout mice. Interestingly, secretory capacity of wild-type mouse islets was restored within hours of glibenclamide washout, and in vivo within 1 month after treatment termination.
Immunostaining showed normal islet size and alpha/beta cell distribution within the islet, and no evidence of apoptosis. This study may
give insight into secondary failure of SU treatment in humans with T2DM. Further studies are required, for example, assessing whether insulin secretion can be restored after a SU treatment break.
Initial SU response and subsequent failure is highly variable.
The UKPDS group examined SU failure in non-insulin-dependent diabetic patients over 6 years. 57 They prospectively followed newly diagnosed T2DM (n = 1305) randomly allocated to chlorpropamide or glibenclamide. By 6 years, 44% had required additional therapy;
48% of those allocated to glibenclamide and 40% on chlorpropamide (p < 0.01). Modeling of beta-cell function concluded that those with lower function were more probable to fail (p < 0.0001).
SU failure rate was dependent on the phenotype at presentation;
higher glucose concentrations at initial presentation, younger age of presentation, lower residual beta-cell reserve and body mass index (BMI) <30.
Gliclazide was shown to cause less secondary beta-cell failure than glibenclamide/glyburide (p < 0.001). 51 This could be explained by its reversible binding to the K ATP channel, and therefore it may not hyper-excite and exhaust beta-cells to the same degree as glibenclamide. There are three other potential explanations for this. The first relates to antioxidant activity, that gliclazide has potent free radicalscavenging activity mediated by an azabicyclo-octyl ring on the SU core. 58 The second is that chronic hyperglycaemia may induce oxidative stress, reduction in beta-cell mass and tissue damage. 59 The third is that hyperglycaemia induces mitochondrial superoxide production, activating the uncoupling of protein 2, decreasing the ATP:ADP, producing an overall reduction in insulin secretion. 60 Harrower concluded that gliclazide is the most potent SU with the lowest incidence of hypoglycaemia and reduced secondary failure rates. 61 The GoDARTS study reported that loss-of-function CYP2C9 variants improve therapeutic response to SU in T2DM and were associated with less SU failure. 66 Incidental users of SUs in Tayside (n = 1073)
were assessed for the impact of the combined CYP2C9*2 and 
| SULPHONYLUREA EFFICACY AND SAFETY
There is no doubt that SUs are effective, both in terms of initial showed greater HbA1C reduction in the first 6 months of treatment. 10 However, SU treatment failure was the highest versus comparators by the end of the study. 68 A recent re-analysis of the ADOPT study by the MASTERMIND consortium showed that SUs were much more effective than rosiglitazone in non-obese men. In contrast, obese women responded better over 5 years to rosiglitazone than SUs. A large Canadian multicentre study (n = 114 sites) found gliclazide to be safe, well tolerated and efficacious in most patients studied. 71 Gliclazide (80-320 mg daily) was given for 3 months to T2DM patients (n = 411) suboptimally controlled with diet or monotherapy. However, it should be noted that SGLT-2 inhibitors, now commonplace second line therapy with excellent outcome data, are not included in this analysis. The primary outcome is time to primary failure (HbA1c ≥7%) while receiving metformin (up to 2000 mg per day) and the randomly assigned study medication by intention-to-treat. The secondary outcome is time to secondary failure (HbA1c >7.5%). GRADE will record other attributes such as CV disease, safety, tolerability and cost-effectiveness; however, it is not powered as a clinical outcomes study.
| EXPLORING SULPHONYLUREA CARDIOVASCULAR SAFETY
SUs have chequered CV outcomes, however, it is important to note that many early conclusions were derived from studies which were not originally powered to evaluate these outcomes. Thus, the detrimental results of studies may have been overstated. It is hoped that the results of CAROLINA CVOT which reports in 2019 and compares linagliptin with glimepiride will establish once and for all whether SUs (albeit only glimepiride) increase CV risk 15 ; this follows on from CARMELINA CVOT which established the CV safety of linagliptin versus placebo. 72 In the 1970s, the University Group Diabetes Program (UGDP)
was one of the first randomized trials in diabetes. [73] [74] [75] Patients (n = 200) were randomized to insulin, tolbutamide or placebo 
in the placebo group) causing the U.S. Food and Drug Administration (FDA) to issue a black-box warning against SUs. 76 Of note, tolbutamide also displayed increased risk of CV events compared with insulin therapy, which also causes hypoglycaemia. However, UDGP design and conduct are still disputed, as the tolbutamide cohort had increased CV events by the study outset. 77 The UKPDS provided clearer guidance 78 observing that reducing glucose exposure (HbA1c 7.0% vs. 7.9% over median 10 years) with SU or insulin therapy reduced the risk of "any diabetes related endpoint" by 12% and microvascular disease by 25%, with a 16% trend to a reduced risk of myocardial infarction (MI) (p = 0.052). UKPDS displayed no increase in CV death, MI or sudden death with SU use.
However, the study was not powered to evaluate these outcomes. Observational studies tend to report increased CV risk for SUs versus comparators (often metformin). It is difficult to draw conclusions from observational studies as there is scope for considerable bias, even after rigorous methods to account for this.
| DOES TISSUE SPECIFICITY OF SULPHONYLUREAS AFFECT CARDIOVASCULAR SAFETY?
A recent study used genetic variation in SUR to predict the causal association of K ATP channel closure (mimicking SU action) on coronary heart disease (CHD) outcomes 83 ( Figure 3 ). In 120 286 UK Biobank participants, the p.A1369S SUR1 variant described earlier was associ- In the SPREAD DIMCAD study, first generation SUs were associated with increased CV events. This may be because of their lower affinity for pancreatic beta-cell SUR1, but higher affinity for cardiac and vascular smooth muscle SUR2, which may interfere with ischaemic cardiac preconditioning. 84 Second generation SUs have an affinity for SUR1 with no effect on cardiac or vascular smooth muscle SU receptors 27, 85 which upholds the findings of Gribble et al. 25, 27 Nonselective blockade of myocardial SUR receptors worsens postischaemic wall function by shortening the action potential. 95 This was similarly shown in rat models comparing glibenclamide with gliclazide on myocardial infarct size. 57 Glibenclamide, but not gliclazide, was noted to exacerbate ischaemic/reperfusion injury along with association with deterioration in LV function post-MI in diabetic hearts. the data for gliclazide rather than non-selective SUs such as glibenclamide. As shown, the evidence suggests that gliclazide has efficacy in terms of glycaemic control, 56 lower secondary failure rates, 49 and is equivalent to pioglitazone in terms of incidence of CV events in the TOSCA.IT study. 70 Glipizide is probably the most selective SU and should be considered. However, as CV outcomes for glipizide are not well reported, the evidence does not point to a clear alternative in the absence of gliclazide. [96] [97] [98] We believe that the issues of hypoglycaemia and secondary failure may be minimized by considering the physiological action of SUs, the insights gained from the treatment of patients with NDM, and the beneficial outcomes of slow release lower dose preparations of SUs.
These data suggest that SUs are used in too high doses, and lower doses of SUs may be only slightly less effective yet have reduced risk of SU and secondary failure. With research into these areas it may be possible to modernize the use of this old drug class and prevent a useful drug class in the management of diabetes disappearing from use.
